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Multiorgan mRNA misexpression in murine autosomal reces- Polycystic kidney disease (PKD) is the term applied
sive polycystic kidney disease. to a group of inherited disorders characterized by the
Background. BALB/c mice homozygous for the cpk muta- presence of cysts in the kidney, however, multiple organstion develop a form of polycystic kidney disease (PKD) with
are usually affected. Renal pathologies found in essen-multiorgan pathology similar to human autosomal recessive
tially all forms of PKD include increased fluid secretion,PKD. Messenger RNA expression in multiple affected organs
was analyzed to determine if common gene cascades were matrix remodeling, cellular proliferation and apoptosis
misexpressed in the cystic kidney and extrarenal sites of dis- with an altered differentiation of the epithelial cells lin-
ease. In cystic kidneys, misexpressed mRNAs were found in ing the renal cysts [1]. The two most common forms ofone of four general groups: proliferation/cell growth, apoptosis,
PKD represent conditions that are inherited as eitherdifferentiation or extracellular matrix.
autosomal dominant (AD) or autosomal recessive (AR)Methods. RNA was isolated from kidney, liver and pancreas
of cystic and normal BALB/c-cpk mice. Using Northern blot traits. ARPKD is the more rapidly progressive of these
hybridization and ribonuclease protection assays (RPA), the conditions, which can lead to uremia in infants. While
expression of several genes thought to be associated with PKD, these two common forms of PKD primarily target thenamely c-myc, epidermal growth factor receptor (EGF-R) and
kidney, affected individuals with either of these condi-PKD-1, were evaluated. RPAs were used to assess mRNA
tions exhibit multiorgan pathology that typically involvesexpression of cyclins and members of the bax/bcl-2 family. In
addition, kidney, liver and pancreas were immunostained for the liver. Many different genes can induce the develop-
c-Myc and PCNA. ment of polycystic kidneys; however, the gene responsi-
Results. Cystic kidney, liver and pancreas all exhibited simi- ble for human ARPKD (the PKHD1 gene) is localizedlar patterns of mRNA misexpression of c-myc, EGF-R and
to human chromosome 6 and recently was identified asPKD-1. In addition, a number of cell proliferation and apopto-
fibrocystin [2, 3]. PKD in the pck rat is caused by asis-related mRNAs also were elevated in cystic kidney and
pancreas. Renal epithelial cells expressing proliferation-associ- mutation in the PKHD-1 gene [2]. While none of the
ated proteins [c-Myc and proliferating cell nuclear antigen spontaneous murine models of ARPKD exhibit defects
(PCNA)] were nearly absent in normal kidney; however, cells in the same genetic locus, several mouse models exhibitof cystic and non-cystic renal tubules plus liver and pancreatic
multiorgan pathology similar to that seen in the humancyst exhibited an increased number of nuclei labeled with anti-
disease, including the cpk mouse. Recently, the cpk genebodies to these proteins.
Conclusions. These data suggest that similar pathologic was cloned [4]. The cpk gene product, cystin, is a protein
mechanisms (including the expression of c-myc, EGF-R, PKD-1, found in cilia [4]. The present investigation utilized the
cyclin, and bax/bcl-2 family mRNAs) may be responsible for BALB/c-cpk/cpk model, which exhibits kidney, liver andthe development of cystic changes in kidney, liver and pancreas
pancreatic pathology [5] to evaluate multiorgan mRNAin murine autosomal recessive PKD. Treatments targeting
misexpression in ARPKD.these similarly misexpressed mRNAs may be efficacious in
ameliorating the cystic pathology in the kidney as well as the A number of laboratories have identified mRNAs that
other affected organs in ARPKD. are misexpressed in the kidneys in various rodent models
of PKD (Table 1). The types of mRNAs that have been
found to be misexpressed in cystic kidney (Table 1) can
Key words: PKD-1, Balb-c-cpk/cpk mice, c-myc, EGF receptor, clus-
be divided into four groups, those associated with: (1) pro-terin (SGP-2), apoptosis, cell differentiation, proliferation, extracellu-
lar matrix, cystic kidney. liferation [that is, c-myc, histone H4, epidermal growth
factor (EGF), EGF receptor], (2) apoptosis (that is, bcl-2Received for publication April 4, 2002
family members, caspases), (3) epithelial differentiationand in revised form May 31, 2002
Accepted for publication June 24, 2002 (that is, E-cadherin, SGP-2), and (4) extracellular matrix
(that is, collagen, fibronectin, laminin, matrix metallo- 2002 by the International Society of Nephrology
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proteinases). While there have been a number of misex- with RNase, precipitated, and reconstituted in gel loading
buffer. The renal, hepatic and pancreatic RNA hybridspressed mRNAs identified with the development of the
renal cystic pathology, there are no published studies were separated by electrophoresis using a 5% acrylamide
gel containing 12 mol/L urea. After electrophoresis, theon misexpressed mRNAs associated with the extrarenal
pathology of PKD. To our knowledge, the present study gel was dried onto blotting paper at 50C, and apposed
to X-ray film for autoradiography. The relative expres-is the first to specifically determine similarly misex-
pressed mRNAs in the renal and extrarenal cystic organs sion of these specific messages was determined by densi-
tometric evaluation of the autoradiographs.in PKD. We used the BALB/c-cpk mouse model since
it has well established extrarenal pathology.
Immunolocalization
Localization of c-Myc and proliferating cell nuclear
METHODS
antigen (PCNA) was performed using paraffin sections
BALB/c-cpk/ heterozygous male and female mice of kidney, liver and pancreas as previously described
were crossed to generate the litters used in this study. [5]. The sections were treated with methanolic peroxide,
The renal and extrarenal pathology in this model of followed by normal goat blocking serum, and then incu-
ARPKD were previously described [5]. bated with a primary antibody to c-Myc (1:25, catalog #
sc-764, a rabbit polyclonal antibody to human c-Myc; 18
RNA isolation and Northern hybridization
hours at 4C; Santa Cruz Biotechnology, Inc., Santa Cruz,
Total RNA from normal and cystic 17-day-old BALB/ CA, USA) or PCNA (1:100, catalog # M0879, a mouse
c-cpk kidney, liver and pancreas was isolated as pre- monoclonal antibody to human PCNA; 30 minutes at
viously described [5]. Briefly, kidney, liver and pancreas room temperature; Dako Corp., Carpinteria, CA, USA).
were separately homogenized in Tri-Reagent (Molecular An avidin-biotin-complex method (Vector Laboratories,
Research Center, Inc., Cincinnati, OH, USA) and RNA Inc., Burlingame, CA) with nickel enhanced diamino-
isolated according to the manufacturer’s instructions. benzidine (DAB) as the chromagen was used to visualize
Renal, hepatic or pancreatic RNA were each subjected the antibodies. Detection of the PCNA antibody was
to gel electrophoresis (1% agarose/formaldehyde) to enhanced using a VECTOR M.O.M. Kit (catalog # PK-
separate RNA by size, transferred to a Zetabind mem- 2200; Vector Laboratory) to eliminate background stain-
brane (Cuno, Inc., Meridien, CT, USA), and stained with ing from endogenous mouse immunoglobulins. c-Myc
methylene blue to ensure equal amounts of RNA in each and PCNA proteins were viewed using light microscopy.
lane. After baking (2 hours at 80C), the blots were Quantitative analysis of c-Myc and PCNA in cystic and
hybridized overnight at 65C. DNA probes for c-myc, non-cystic tubules was performed using coded sections.
clusterin (SGP-2), preproEGF, EGF receptor (provided c-Myc and PCNA staining of cystic and non-cystic tu-
by E. Adamson, La Jolla, CA, USA), PKD-1 (provided bules was determined as: labeled cells per 100 m of
by G. Germino, Baltimore, MD, USA) and Histone H4 cyst wall and labeled cells per 25 non-cystic tubules,
were random prime labeled with 32P-dCTP (Rediprime respectively. Normal rabbit serum replaced the primary
II; Amersham Pharmacia Biotech, Arlington Heights, antibody in negative control sections, while intestine was
IL, USA). Hybridized blots were washed and apposed used as a positive control tissue.
to X-ray film for autoradiography. Densitometric quanti-
Apoptotic and mitotic indextation was performed to determine the relative expres-
sion of specific mRNAs as previously described [5]. The Histological sections of kidney, liver and pancreas
Northern blot hybridization studies were run in duplicate from cystic and normal mice were evaluated from coded
with RNA from different mice. slides. Apoptotic cells exhibited morphological changes
including nuclear condensation and nuclear fragmenta-
Ribonuclease protection assays tion. Epithelial cells in metaphase, anaphase or telophase
Ten microgram samples of total RNA from kidney, liver were considered to be in mitosis. The percent of the cells
and pancreas of 17-day-old normal and cystic BALB/ undergoing mitosis (mitotic index) or apoptosis (apo-
c-cpk mice were hybridized overnight at 56C in solution ptotic index) were quantified for hepatic biliary epithelia,
with riboprobes to evaluate cyclin (catalog # 45620P; pancreatic duct epithelia, normal distal nephron and cys-
PharMingen, San Diego, CA, USA) or apoptosis-related tic collecting duct.
(catalog # 45354P, PharMingen) mRNA expression. The
Statistical analysisriboprobes were transcribed using a T7 RNA polymerase
in vitro transcription system (catalog # P1440; Promega Statistical analysis of serum urea nitrogen, total body
Corp., Madison, WI, USA) according to the manufacturer’s weight, kidney weight as a percent of body weight, hema-
instructions. Anti-sense RNA probes were radiolabeled tocrit and bile duct diameter were performed using anal-
ysis of variance (ANOVA; P  0.05) with the aid ofwith [32P] CTP. After hybridization, the RNA was treated
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ney (Fig. 2). Renal expression of cyclins A2 and B1
mRNAs were also elevated five- and sixfold, respec-
tively, in cystic mice (Fig. 3). In spite of these data indicat-
ing an increased expression of proliferation associated
mRNAs, renal histone H4 mRNA concentrations were
not different in normal and cystic mice. While bcl-X
mRNA expression was not different in normal and cystic
mice, bak, bax, bcl-2 and bad mRNA levels were in-
creased 7.5-, 1.6-, 7- and 2.4-fold, respectively, in the
cystic kidney (Fig. 4). The expression of two mRNAs,
which are thought to represent the immaturity of the
collecting ducts, SGP-2 (clusterin) and PKD-1, were in-
creased 14- and twofold, respectively, suggesting that
the cystic epithelial cells express characteristics of an
immature epithelium.
In the liver, the pathology appears to be confined to
a small population of cells, the intrahepatic bile ducts.
Northern blot hybridization studies indicated that he-
patic levels of c-myc and EGF-R mRNAs were increased
1.8- and threefold, respectively, in cystic mice (Fig. 2).
Expression of all the other mRNAs evaluated was not
Fig. 1. Multiorgan pathology. Cystic pathology in BALB/c-cpk/cpk
different between normal and cystic liver.mice. Grossly (a ), common bile duct (arrow) dilation is evident in cystic
mouse on right. Note the enlarged cystic kidneys in this 15-day-old cpk/ Pancreatic expression of EGF-R, PKD-1 and histone
cpk mouse (arrow). The cystic pathology is evident in (b ) kidney, (c ) H4 mRNAs were elevated in cystic mice 8-, 24- and 2.5-
liver and (d ) pancreas of BALB/c-cpk/cpk mice.
fold, respectively (Fig. 2). However, c-myc mRNA levels
were not consistently different between cystic and nor-
mal pancreas. Expression of cyclin C and D1-3 (Fig. 3)
MINITAB software (State College, PA, USA). Apo- mRNAs were increased 8-, 20-, 2.5- and 7-fold respec-
ptotic index data for normal appearing distal nephron tively, and bcl-X, bak, bax, bcl-2, and bad (Fig. 4) were
cells from normal and cystic kidney were compared using increased 18-, 15-, 22- 13- and 15-fold respectively, in
a one-tailed analysis. Data are presented as mean SEM. cystic pancreas.
Altered protein staining
RESULTS
While there was minimal staining evident in normal
The BALB/c-cpk/cpk mouse has prominent kidney,
kidney, liver and pancreas, c-Myc and PCNA protein
liver and pancreatic pathology (Fig. 1 a-c) with an ele-
staining was prominent in these cystic organs (Fig. 5).vated relative kidney weight, SUN and common bile
This staining was particularly prominent in nuclei of epi-duct diameter (Table 2).
thelial cells lining cysts in these organs; however, c-Myc
and PCNA were also localized in some nuclei of renalAltered mRNA expression
epithelial cells of non-cystic renal tubules (Fig. 5).mRNA expression of genes thought to be associated
with PKD have not been examined in the extrarenal Apoptotic and mitotic cell indices
tissues of a murine model exhibiting multiorgan involve-
The percent of epithelial cells exhibiting evidence ofment. The misexpression of mRNA was evaluated in 17-
apoptosis was significantly increased in the cystic kidneyday-old normal and cystic BALB/c-cpk mice. Epidermal
and liver compared to that seen in the normal mice. Ingrowth factor receptor, EGF-R mRNA was overexpressed
kidney, cystic and non-cystic tubules similarly exhibitedin all organs examined, while PKD-1 and c-myc messages
increased apoptosis (Table 3). In the hepatic biliarywere each overexpressed in two of the affected organs.
ducts, the cystic mouse also exhibited increased epithelialA number of mRNAs associated with apoptosis and pro-
apoptosis compared with normal mouse liver. The mi-liferation were overexpressed in cystic kidney and pan-
totic index was only increased in cystic epithelia fromcreas. In the kidney, c-myc mRNA levels were increased
the kidney. It is unclear whether the severe azotemia insevenfold in BALB/c-cpk/cpk mice (Fig. 2). Expression
cystic mice influenced the apoptosis and mitosis ratesof EGF mRNA was severely diminished, while EGF-R
message expression was increased twofold in cystic kid- described herein.
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Table 2. BALB/c-cpk mouse disease at 17 days of age
KW/BW Hematocrit
Body weight Common bile duct SUN
Phenotype g % diameter in mm mg/dL
Normal 10.50.28 1.600.025 29.91.42 0.460.014 13.00.85
(N19)b (N16) (N14) (N16) (N17)
Cystic 7.350.26a 18.040.68a 33.51.03 2.480.17a 108.912.8a
(N23) (N23) (N20) (N23) (N19)
a P 	 0.05 from normal
b Number of animals
Fig. 3. Cyclin mRNA expression. Renal, hepatic and pancreatic
mRNA expression of cyclin genes from normal and cystic BALB/c-cpk
mice by ribonuclease protection assay. Compared to normal kidney,
cyclin A2, B1 and D2 mRNA expression was increased in cystic kidney
while cyclin C and D1 were elevated in the cystic pancreas. None of
the cyclin mRNAs were lower in the cystic kidney, cyclin A1, B1 and
D2 were lower in the cystic pancreas and cyclin A2, B1, C and D2 were
lower in the cystic liver. The cystic biliary duct cells of liver represent
a relatively small percentage of the cells in liver; therefore, it is unclear
Fig. 2. mRNA expression in kidney, liver and pancreas. Renal, hepatic exactly which cell population is responsible for these mRNA data.
and pancreatic mRNA expression from normal and cystic BALB/c-cpk However, PCNA staining was most prominent in cells lining the intra-
mice by Northern blot hybridization. The expression of c-myc, EGF-R, hepatic biliary cysts. L32 and GAPDH mRNAs are shown as controls.
PKD-1 and histone H4 were elevated in cystic organs. Renal EGF N  normal, C cystic.
mRNA was severely diminished, while EGF-R mRNA was increased
twofold in cystic kidney. The elevated SGP-2 suggests a continued
immaturity of the renal collecting duct. Methylene blue staining of 28S
and 18S rRNA is shown as a control for RNA loading. N  normal,
ptosis-associated genes in the kidney, liver and pancreasC  cystic.
of BALB/c-cpk mice. To our knowledge this is the first
study to evaluate the multiorgan misexpression of mRNAs
in PKD. Prior mRNA misexpression data from the cystic
DISCUSSION kidney implicated several pathways thought to contrib-
ute to the pathogenesis of renal cysts. We evaluatedRenal gene misexpression is a feature of polycystic
kidney disease in rodents and reflective of the changes some of these pathways and mRNAs to determine if
they are potentially involved in the development of thein cell proliferation, apoptosis, differentiation and mor-
phogenesis of cysts (Table 1). The present study exam- extrarenal pathology. In kidney and liver, c-myc mRNA
was overexpressed while PKD-1 was overexpressed inined the expression of mRNAs of proliferation and apo-
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Fig. 5. Immunolocalization of c-Myc and PCNA. ImmunolocalizationFig. 4. bax/bcl-2 family mRNA expression. Renal, hepatic and pancre-
of c-Myc and PCNA protein in kidney, liver and pancreas of BALB/atic mRNA expression of apoptosis-associated genes from normal and
c-cpk/cpk mice. PCNA staining is localized to the nuclei of cyst liningcystic BALB/c-cpk mice by ribonuclease protection assay. Compared
epithelial cells in (a) kidney, (b) liver and (c) pancreas of cystic mice.to normal kidney, bak, bax, bcl-2 and bad message levels were elevated
C-Myc staining was evident in nuclei of cells lining renal (d), liver (e)in cystic kidney and bcl-2 was reduced in liver, while bcl-X mRNA
and pancreas ( f ) cysts. Nuclear PCNA and c-Myc staining was alsoexpression was unchanged in cystic kidney and liver. Bcl-x, bak, bax,
observed in (a and d) renal epithelial cells lining non-cystic tubules. Asbcl-2 and bad mRNA levels all were elevated in the cystic pancreas.
a positive control, PCNA and c-Myc staining were particularly promi-L32 and GAPDH mRNAs are shown as controls. N  normal, C 
nent in nuclei of cells in the crypts of the intestine (data not shown).cystic.
(Magnification: a-c, 
250; d-f, 
500)
the cystic kidney and pancreas. C-myc has long been
other organs [37]. Therefore, animal models of PKDimplicated in the pathogenesis of renal cysts in rodent
would be expected to exhibit multiorgan pathology simi-PKD [9, 18, 35]. However, c-myc mRNA appears to be
lar to that seen in humans. Several animal models ofincreased in both cystic and non-cystic tubules [5, 6].
PKD, including cy/ rats [20], PKD-1 knockout miceSimilar patterns of staining for PCNA and c-myc suggest
[38], PKD-2 knockout mice [39], BALB/c-bpk mice [40],the c-myc expression may be causally related to the epi-
CD-1-cpk/cpk mice [41], Tg737 (orpk) mice [42] andthelial proliferation in PKD. Histone H4 mRNA was
BALB/c-cpk/cpk mice [5] display multiorgan pathologyoverexpressed in non-renal cystic organs, further evinc-
that can mimic that seen in humans. It is unclear whethering a role for increased proliferation in PKD. Renal
cyst formation in kidney and extrarenal sites uses theexpression of histone H4 was not increased in the cystic
same or similar processes. Gene misexpression appearskidney, similar to our previous findings in the BALB/
to contribute to the renal changes in PKD models (Tablec-cpk mouse [5]; however, it was found to be overex-
1), but there are no published studies describing changespressed in cystic kidney of the C57BL/6J-cpk mouse [9].
in mRNA expression in extrarenal pathology. In animalInterestingly, renal EGF mRNA expression was reduced
models and human PKD the misexpressed genes thoughtwhile the EGFR was overexpressed in all three cystic
to participate in the pathogenesis of renal cysts include:organs. It is unclear why distal tubular expression of
PKD genes (PKD-1, PKD-2), c-myc, EGF and/or EGF-R.EGF is reduced in PKD in rodent models [11, 12, 21]
Therefore, the multiorgan misexpression of these genesand human ADPKD [36]. However, the relative absence
is the focus of our evaluation of murine ARPKD inducedof renal EGF expression may serve to up-regulate the
by the cpk gene in BALB/c mice. The general featuresexpression of the EGFR in the cystic kidney. The overex-
of cyst formation include: proliferation, apoptosis, fluidpression of proliferation- or growth-related mRNAs con-
secretion and matrix remodeling, and we assume thatfirms the role of cell proliferation as a necessary compo-
these overexpressed genes contribute to one or more ofnent in the pathogenesis of cysts, in kidney and other
these processes in the pathogenesis of PKD.organs.
Polycystin-1 protein, or PKD-1 mRNA is expressedBoth AR and AD PKDs are characterized by the
in a wide variety of organs including: kidney, liver, pan-development of pathological changes in multiple organs.
creas, lung and brain [43–45]. PKD-1 protein expression isAlthough renal cysts are the predominant pathology,
individuals with PKD also may develop pathology in highest during organ development, but is normally down-
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Table 3. Apoptotic and mitotic indices
Apoptosis Mitosis
Normal mouse Cystic mouse Normal mouse Cystic mouse
Kidney
Normal tubule 0.210.098 0.550.16a 0.0690.069 0.210.10
Cystic tubule 0.750.14a 0.610.16a
Hepatic biliary duct 0.520.25 1.860.34a 0.150.15 0.430.17
Pancreatic duct 0.960.48 1.510.55 0.670.16 0.420.27
N  7 for all groups.
aP 	 0.05 for difference from corresponding values from the normal mouse
regulated by adulthood [45–47]. The developmental ex- renal, pancreatic and hepatic cysts. The unregulated ex-
pression of c-myc evident in all cystic epithelia suggestspression pattern of polycystin-2, or the PKD-2 gene, has
been described to mimic that of PKD-1 [48]. Recent that c-myc is critical to the development of cysts. Ele-
vated c-myc expression is associated with increased ratesstudies also suggest a minimal overlap in cellular location
of polycystin-1 and -2 in various nephron segments [49], of apoptosis and proliferation [58], both of which are
important processes in PKD. Overexpression of c-mycsuggesting an independence in action of these proteins.
However, a single mutated PKD-1 in combination with may cause increased proliferation and apoptosis that is
observed in PKD [37, 59, 60]. c-myc-induced apoptosisa mutated PKD-2 gene can lead to cyst formation [50],
supporting a cooperative role for polycystins in cyst for- and proliferation are inhibited by bcl-2 in a mouse model
of hepatocellular carcinoma [61], but those cellular pro-mation in vivo. Overexpression of a functional PKD-1
transgene also leads to cyst formation [51]. Are cysts cesses are apparently bcl-2 independent in c-myc trans-
genic mice with PKD [62] and BALB/c-cpk kidney sincecaused by too much polycystin, too little polycystin, or
are both conditions cystogenic? At the present time, the bcl-2 is overexpressed. The misexpression of mRNAs
for cyclin and bax/bcl-2 families suggest that prolifera-mechanisms by which the PKD-1 and/or PKD-2 genes
stimulate renal cyst formation are unknown. Despite tion and both pro- and anti-apoptotic mechanisms are
being stimulated in the cystic condition. However, apo-some disagreement on the location and relative amounts
of polycystin in the nephron segments of the kidney, re- ptosis appears to play an important role since bcl-2
knockout mice develop PKD [63, 64]. In the presentnal cysts from adults with ADPKD-1 or ADPKD-2 ap-
pear to generally exhibit strong staining for polycystin study, pro-apoptotic (bak, bax and bad) and anti-apo-
ptotic (bcl-2) mRNAs were elevated in cystic kidney and[52]. In the current study, cystic kidney and pancreas
both exhibited overexpression of PKD-1 mRNA. The pancreas. Since the evaluation of apoptotic figures in
the three organs identified elevated apoptosis in kidneypathology seen in these two organs is similar to that seen
in PKD-1 knockout mice [38]. However, hepatic cysts (non-cystic and cystic tubular epithelia) and hepatic bili-
ary ducts, it appears that pro-apoptotic factors dominatein human ADPKD [53], PKD-1 knockout mice [54] and
old cpk/ mice [55] appear to result from a loss of the (Table 3). However, the specific role of apoptosis in the
pathogenesis of PKD is still unclear [65].normal allele (that is, the loss of heterozygosity), sug-
gesting that there should be a decrease in polycystin-1 Epidermal growth factor is produced by the kidney
and appears to be a regulator of renal function. However,in hepatic cysts of BALB/c-cpk/cpk mice. It is unclear
at present why the cystic liver, pancreas and kidney over- the role of EGF and its receptor (EGF-R) in the patho-
genesis and progression of PKD is unclear. EGF inhibitsexpress PKD-1, but it may represent a continued imma-
turity of the cystic epithelium or an altered phenotype developmentally-regulated apoptosis in the kidney [66].
Neonatal injections of exogenous EGF have been shownthat overexpresses the polycystin similar to many human
ADPKD renal cysts. to inhibit cystic renal enlargement and/or renal dysfunc-
tion in infantile forms of PKD [5, 67]. Similarly, neonatalc-myc is abnormally expressed in proliferative or neo-
plastic processes such as PKD and numerous cancers. EGF-treatment inhibits apoptosis in neonatal unilateral
ureteral obstruction [68]. Therefore, the early protectiveOverexpression of c-myc mRNA is described in rodent
(c-myc transgenic mice [35]; cpk mice [5, 9]; cy rat [20]; effects of growth factors, such as EGF, may involve inhi-
bition of apoptosis. However, promotion of proliferationpcy mice [18]) and human [56] PKD. Furthermore, over-
expression of c-myc causes PKD [35], while treatment by members of the EGF family and/or excessive stimula-
tion of the EGF-R also can increase cell proliferationwith c-myc antisense oligonucleotides ameliorates mu-
rine PKD [57]. In the present study, c-myc mRNA was and therefore exacerbate the progression of PKD [18,
69–71]. In the present study, the abnormal expression ofelevated in the cystic kidney and liver. c-Myc protein
was present in many of the nuclei of epithelial cells lining EGF (in kidney) and EGF-R mRNAs in cystic kidney,
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liver and pancreas suggest a role for EGF/EGF-R in the ways may lead to the development of clinically useful
interventions for PKD.multiorgan disease of the BALB/c-cpk mouse.
Renal EGF mRNA expression is severely diminished
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